Skip to content

Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium: Comparison Between Sugammadex Versus Neostigmine

Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium Neuromuscular Blockade In Cases Of Supratentorial Tumors: A Comparative Study Between Sugammadex Versus Neostigmine

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02944175
Enrollment
40
Registered
2016-10-25
Start date
2016-07-31
Completion date
2019-10-01
Last updated
2018-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supratentorial Brain Tumor Surgery

Brief summary

Cholinesterase inhibitors such as Neostigmine and Edrophonium have been used to reverse neuromuscular blockade after surgery. However, these drugs have a relatively slow onset and have adverse effects associated with stimulation of muscarinic receptors. In addition, neostigmine cannot be used to reverse profound blockade. Anesthetics may exert their effects on various facets of cerebral function such as cerebral metabolic rate (CMRO2), cerebral blood flow (CBF), cerebral blood flow-metabolism coupling, intra cranial pressure (ICP), autoregulation, vascular response to CO2 and brain electrical activity. The net result of all these effects of the anaesthetic agents combined with their systemic effects may prove beneficial or detrimental to an already diseased brain. In neurosurgical patients, clear and rapid recovery is required to early assess the neurological status and to maintain the cerebral oxygenation and metabolism within the normal physiological values which may be saved by sugammadex.

Detailed description

The aim of this study is to compare Sugammadex versus neostigmine as a reversal to the neuromuscular blockade of rocuronium in patients undergoing supratentorial tumors resection. Comparison will include hemodynamics, respiratory effort and degree of sedation. Indicators of global cerebral oxygenation and haemodynamics will be calculated using jugular bulb and peripheral arterial blood sampling.

Interventions

DRUGSugammadex

At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S

DRUGNeostigmine

At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists physical class status I - III . * Patients scheduled for elective supratentorial brain tumor resection

Exclusion criteria

* Severe uncompensated cardiac disease. * Severe uncompensated respiratory disease. * Severe uncompensated hepatic disease. * Severe uncompensated renal disease. * Morbidly obese patients. * Documented hypersensitivity to one of the used drugs. * Surgery in sitting position * Surgery in prone position * Patients with altered level of consciousness. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Time to recovery of the train-of-four (TOF) ratio to 0.9For 1 hour after surgeryThe time from start of administration of sugammadex or neostigmine to recovery of the train-of-four (TOF) ratio to 0.9

Secondary

MeasureTime frameDescription
Estimated cerebral metabolic rate for oxygen (eCMRO2)For 6 hours after the start of surgeryeCMRO2=Ca- jO2 x(PaCO2 ∕ 100) Where ……. Ca jO2 is arterio-jugular O2 content difference. * PaCO2 is arterial CO2 tension
Cerebral Extraction Rate of Oxygen (CEO2)For 6 hours after the start of surgeryCalculated as the differences between arterial and jugular bulb O2 saturations, CEO2 = SaO2 - SjvO2
Cerebral Blood Flow equivalent (CBFe)For 6 hours after the start of surgeryWhich is an index of flow metabolism relationship, calculated as a reciprocal of arterio-jugular O2 content difference
Heart rateFor 6 hours after the start of surgery
Blood pressureFor 6 hours after the start of surgery
Central venous pressureFor 6 hours after the start of surgery
Peripheral oxygen saturationFor 6 hours after the start of surgery
Arterio-Jugular oxygen content differenceFor 6 hours after the start of surgeryCa jO2 = CaO2-CjvO
Sedation levelFor 1 hour after extubation
Total dose of neuromuscular blockade usedFor 6 hours after the start of surgery
Total dose of suggamadex or neostigmine usedFor 30 min after the end of surgery
Cumulative opioids consumptionFor 6 hours after the start of surgery
Recovery time (RT)For 1 hour after surgerythe time of restoration of neuromuscular conduction sufficient for extubation from stoppage of anaesthesia till the patient can obey commands
Time between administration of sugammadex or neostigmine to recoveryFor 1 hour after surgeryTime from start of administration of sugammadex or neostigmine to recovery of the train-of-four (TOF) ratio to 0.9
End-tidal carbon dioxide tensionFor 6 hours after the start of surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026